On January 4, 2023 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that John Houston, Ph.D., President and Chief Executive Officer of Arvinas, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT in San Francisco, Calif (Press release, Arvinas, JAN 4, 2023, View Source [SID1234625785]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available here and on the Events & Presentations section of the Investors & Media section of the Company’s website.